Anzeige
Mehr »
Donnerstag, 02.04.2026 - Börsentäglich über 12.000 News
Kritische Rohstoffe: China verknappt Germanium - und diese Aktie könnte zum westlichen Schlüsselspieler werden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40VM0 | ISIN: US8902608392 | Ticker-Symbol: TPM0
Tradegate
01.04.26 | 19:08
12,200 Euro
+16,19 % +1,700
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
TONIX PHARMACEUTICALS HOLDING CORP Chart 1 Jahr
5-Tage-Chart
TONIX PHARMACEUTICALS HOLDING CORP 5-Tage-Chart
RealtimeGeldBriefZeit
11,70011,80001.04.
11,70011,90001.04.

Aktuelle News zur TONIX PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiTonix plans Phase 2 Lyme disease prevention study in 20271
DiTonix plant Phase-2-Studie zur Prävention von Lyme-Borreliose für 20272
26.03.Tonix doses first patient in migraine treatment study4
26.03.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and ...230Intranasal oxytocin blocks the release of calcitonin gene-related peptide (CGRP) in animal models and is the core technology of TNX-1900 for craniofacial pain conditions, including migraine and trigeminal...
► Artikel lesen
26.03.Tonix Pharmaceuticals Holding Corp. - 8-K, Current Report2
23.03.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 20263
18.03.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals to Present at BIO-Europe Spring 20262
TONIX PHARMACEUTICALS Aktie jetzt für 0€ handeln
17.03.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 20265
13.03.Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch13
12.03.Tonix Pharmaceuticals GAAP EPS of -$3.98 misses by $0.82, revenue of $5.39M beats by $2.42M7
12.03.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights1.471TONMYA (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia; through February 27, 2026, more than 1,500 healthcare providers have prescribed TONMYA...
► Artikel lesen
12.03.Tonix Pharmaceuticals Holding Corp. - 10-K, Annual Report1
10.03.Tonix presents fibromyalgia drug data at Poland conference8
10.03.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia8
10.03.Tonix Pharmaceuticals Holding Corp. - 8-K, Current Report3
09.03.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting3
05.03.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development4
03.03.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals to Present Poster on Tonmya at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting2
03.03.Tonix Pharmaceuticals Stock Dips After Nasdaq Uplisting2
03.03.Tonix Pharmaceuticals moves to Nasdaq Global Select Market2
Weiter >>
77 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2